
Benign Conditions
Latest News
Latest Videos

Shorts






Podcasts
CME Content
More News

The approval is supported by data from the phase 3 PIVOT-PO trial, in which tebipenem demonstrated noninferiority to imipenem-cilastatin.

The FDA approved cefepime and zidebactam for adult complicated UTI after ENHANCE-1 showed an 89.0% response rate at test of cure.

A comprehensive guide to the practice-changing, paradigm-shifting studies across benign urologic conditions.

The system is expected to launch initially within Veterans Health Administration spinal cord injury hospitals later in 2026.

The FDA has granted 510(k) clearance to the Glean Abdominal Sensor, expanding the capabilities of the Glean Urodynamics System.

These FAQs outline key updates to the AUA's guideline on recurrent uncomplicated urinary tract infections in women.

A recap of the FDA submissions and regulatory decisions in urology from December 2025.

The application is supported by results from the phase 3 PIVOT-PO trial.

In a phase 3 trial, zoliflodacin demonstrated non-inferior efficacy compared with ceftriaxone plus azithromycin.

The approval is supported by data from the phase 3 EAGLE-1 trial.

A recap of the FDA submissions and regulatory decisions in urology from November 2025.

The test is designed to deliver actionable molecular results in approximately 15 minutes.

The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.

The approval is supported by the phase 2/3 ZEUS trial.

Take a look back at the notable regulatory decisions in benign urology between July and September.




















